Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > Compensation Committee

<< Previous

Bullboard Posts

Next >>

Comment by Pandoraon May 01, 2021 2:22am

256 Views

Post# 33107660

RE:Compensation Committee

PutinKhuylo1 wrote: If this was a required annual filing, there would be more than one on Sedar. I have never seen it before and a search from 2012 shows only the one in question. Anyway, have a great weekend - we're one week closer to the rapture or armageddon lol.

1.4% of the transaction value sounds like it could be a tidy sum.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China